Annual Cash & Cash Equivalents
$9.17 M
+$1.98 M+27.50%
31 December 2023
Summary:
Inhibikase Therapeutics annual cash & cash equivalents is currently $9.17 million, with the most recent change of +$1.98 million (+27.50%) on 31 December 2023. During the last 3 years, it has fallen by -$4.79 million (-34.32%). IKT annual cash & cash equivalents is now -77.51% below its all-time high of $40.75 million, reached on 31 December 2021.IKT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$913.40 K
-$2.17 M-70.41%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly cash and cash equivalents is currently $913.40 thousand, with the most recent change of -$2.17 million (-70.41%) on 30 September 2024. Over the past year, it has dropped by -$13.95 million (-93.85%). IKT quarterly cash and cash equivalents is now -98.05% below its all-time high of $46.84 million, reached on 30 June 2021.IKT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +27.5% | -93.8% |
| 3 y3 years | -34.3% | -98.0% |
| 5 y5 years | +2314.4% | - |
IKT Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -77.5% | +27.5% | -98.0% | at low |
| 5 y | 5 years | -77.5% | >+9999.0% | -98.0% | >+9999.0% |
| alltime | all time | -77.5% | >+9999.0% | -98.0% | >+9999.0% |
Inhibikase Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $913.40 K(-70.4%) |
| June 2024 | - | $3.09 M(+31.2%) |
| Mar 2024 | - | $2.35 M(-74.3%) |
| Dec 2023 | $9.17 M(+27.5%) | $9.17 M(-38.3%) |
| Sept 2023 | - | $14.86 M(+680.1%) |
| June 2023 | - | $1.91 M(-51.9%) |
| Mar 2023 | - | $3.96 M(-45.0%) |
| Dec 2022 | $7.19 M | $7.19 M(+24.3%) |
| Sept 2022 | - | $5.78 M(-82.1%) |
| June 2022 | - | $32.21 M(-12.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $36.61 M(-10.2%) |
| Dec 2021 | $40.75 M(+192.0%) | $40.75 M(-9.1%) |
| Sept 2021 | - | $44.85 M(-4.3%) |
| June 2021 | - | $46.84 M(+387.4%) |
| Mar 2021 | - | $9.61 M(-31.1%) |
| Dec 2020 | $13.95 M(>+9900.0%) | $13.95 M(>+9900.0%) |
| Sept 2020 | - | $16.20 K(+107.7%) |
| June 2020 | - | $7800.00(-40.5%) |
| Mar 2020 | - | $13.10 K(-29.2%) |
| Dec 2019 | $18.50 K(-95.1%) | $18.50 K |
| Dec 2018 | $379.60 K | - |
FAQ
- What is Inhibikase Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual cash & cash equivalents year-on-year change?
- What is Inhibikase Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Inhibikase Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of IKT is $9.17 M
What is the all time high annual cash & cash equivalents for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual cash & cash equivalents is $40.75 M
What is Inhibikase Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, IKT annual cash & cash equivalents has changed by +$1.98 M (+27.50%)
What is Inhibikase Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IKT is $913.40 K
What is the all time high quarterly cash and cash equivalents for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly cash and cash equivalents is $46.84 M
What is Inhibikase Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, IKT quarterly cash and cash equivalents has changed by -$13.95 M (-93.85%)